Friday, November 21, 2014 11:14:29 AM
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=108359484
Yesterdays email and a late reply from Dr S.
eugeneseymourmd@mac.com
8:50 PM (11 hours ago)
If I remember correctly we did 8, sent them out for animal testing, took the best two, expanded them to 8, sent out again and then choose the best one
Not doing that with Ebola in the interests of time. Making many more and sending them ALL out at the same time
Speeds up the process
Thus it takes longer on the front end to make all the candidates but shorter on the back end since all of the testing can be done together
Went to visit the plant yesterday
Absolutely blown away by the speed of the move-in of most of the equipment in the past two months
The place really took my breath away
There is nothing like it anywhere in the world
It will eventually be seen as a model for all nanotechnology plants world-wide
The attention to detail is really amazing
I’d love to do a video tour but probably isn’t smart from a competitive point of view
Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
eugene@nanoviricides.com
www.nanoviricides.com
310-486-5677
"NNVC" on the New York Stock Exchange
On Nov 19, 2014, at 1:58 PM,I wrote:
Sir from your release of information,
And this 100% survival result with FluCide is a fact.
So we can estimate the same success for the next TOX.
This is a serious prediction.
Could you tell us how many different iterations of ligands Dr. Diwan tried before such good results?
An approximate is ok. It could have been in the hundreds or thousands. I have no idea, but think the answer would help your loyal supports.
Another_voice_2, boB
The SwingTrade Portfolio is up 42.1% YTD through 8/8/2014, 83.5% in 2013, and 537.4% since inception.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105141243
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM